Piramal Pharma Ltd News

Nifty Pharma index hits record high; Sun, Laurus, Zydus, Sai rally up to 6%

Among others, Mankind Pharma, Ipca Laboratories, Torrent Pharmaceuticals, Divis Laboratories, Cipla and Aurobindo Pharma were up 2% each in Friday's trade.

Piramal Pharma soars 15% in weak market on huge volume post Q2 results

With H2 typically stronger than H1, Piramal Pharma's management said it is well-positioned to deliver a strong FY performance, supported by healthy order book and encouraging customer engagement.

Piramal Finance Q2FY27 results: Net profit zooms 67% to ₹545 crore

Non-bank lender Piramal Finance on Monday reported a 67 per cent jump in net profit to Rs 545 crore for the September quarter, helped by core income growth and improvements in costs. The company's core net interest income grew 35 per cent to Rs 1,530 crore due to a 24 per cent growth in assets under management and a 0.35 per cent expansion in net income margin to 6.5 per cent. The cost-to-income ratio improved sharply to 52.1 per cent during the reporting quarter from 61.2 per cent, helping the bottom line. Stressing that the company is uniquely positioned in the NBFC universe, as it does not see a threat to margins amid the rising interest rate environment, its Managing Director and Chief Executive Jairam Sridharan exuded confidence that it will be able to expand NIMs by up to 0.20 per cent over the next year. When asked how such a feat will be possible despite rising rates, which increase an NBFC's borrowing costs, Sridharan explained that the rating upgrade it received recently

Piramal Pharma cuts exposure to Chinese raw materials to reduce supply risk

Piramal is among global drugmakers increasingly seeking to reduce their reliance on China for pharmaceutical ingredients and manufacturing, amid rising geopolitical tensions

Pharma shares shine: Divi's, Laurus hit new highs; zoom up to 91% in FY27

India's CRDMO sector growth rebounded to 19% YoY in Q1FY27 versus just 9% YoY in the March 2026 quarter, marking the highest growth level since the December 2024 quarter, notes Jefferies.

Piramal Pharma eyes mid-teens growth in FY27, prioritises organic expansion

Higher capacity utilisation, operating leverage and broad-based demand across CDMO, hospital generics and consumer healthcare are expected to support margins in FY27

Glenmark, Biocon, Aurobindo slip 3% on Trump's generic drug tariff plan

The US President Donald Trump announced a proposal to impose phased tariff (up to 200%) regime on imported generic medicines aimed at encouraging pharmaceutical manufacturing within the United States.

Trading ideas today: Piramal Pharma, Authum Investment, Vaibhav Global

Kunal Kamble of Bonanza has recommended three stocks to buy today - Piramal Pharma, Authum Investment, Vaibhav Global

Piramal Pharma shares rise 4% on successful closure of US FDA inspection

Piramal Pharma said that the US FDA has issued an Establishment Inspection Report (EIR) for its Sellersville facility, and the inspection has now been successfully closed.

Stocks to buy: Piramal Pharma, HSCL among 3 top bets by Choice Broking

Stocks to buy: Here's why Aakash Shah, technical analyst at Choice Broking recommends a 'Buy' on Piramal, Aza Engineering and Himadri Speciality Chemical this week.

Nifty Pharma extends rally, up 2%; Piramal Pharma, Laurus gain up to 10%

Analysts said that a combination of defensive buying, strong earnings visibility, export tailwinds, and sector rotation is driving the rally in pharma stocks.

Piramal Pharma to stay away from generic GLP-1 race amid global rush

Piramal Pharma is avoiding the crowded GLP-1 peptide market, focusing instead on niche therapies and specialised manufacturing to drive CDMO growth in FY27